Navigation Links
GelFix(TM) Posterior Spinal Distraction Implant Receives CE Mark
Date:3/8/2010

CRANBURY, N.J., March 8 /PRNewswire/ -- Replication Medical, Inc., a developer of proprietary, hydrogel based products for the spine and other surgical applications, announced today that it has received a CE mark for its GelFix Posterior Spinal Distraction implant.    A CE mark is the quality assurance certification requirement recognized by members of the European Union for sales into those countries.

The GelFix device is a one-piece posterior spinal implant made from HPAN, a biocompatible hydrogel which exhibits desirable mechanical properties including compressive resistance with a dynamic response.  The GelFix distraction implant is used as a spacer between the spinous processes to provide separation and prevent nerve pinching.  The product is available in three sizes to fit the typical range of spinal stenosis patients.

The CE mark for this implant follows the approval the company received last year from the Food and Drug Administration (FDA) to market its EnGuard™ Vessel Guard.  The EnGuard device is indicated for use as a protective cover for blood vessels following anterior spine surgery and is composed of the same biocompatible polymer.

The EnGuard Vessel Guard is the first in a series of innovative products based on their proprietary hydrogel technology that the company is launching this year in the United States.

Commenting on these developments, Ann Prewett, President and CEO, said, "The GelFix implant provides a unique, minimally invasive solution for treating spinal stenosis, a leading cause of back pain."   The GelFix device acts as a dynamic spacer, compressing under load yet maintaining separation of the interspinous space.  In this manner, some of the complications associated with rigid spacers such as breakage of the bones of the spinous process or subsidence may be avoided.    

"Our products provide a technologically advanced alternative to the conventional metal and hard plastic implants which have dominated orthopedics and spine to date.   Replication Medical looks forward to entering these markets because we offer the only technology which provides a biomimetic solution to treat these medical conditions," she explained.

The GelFix interspinous implant may not only reduce pain, but also increase the mobility of the patient.   "The key to the procedure is the minimally invasive technique which can be used to implant the device.  We insert the implant between the appropriate spinous processes and in 8-10 hours, the implant increases in size and gives us the stability that we need," said Carl Lauryssen, M.D., one of Replication Medical's surgeon advisors.

The GelFix Posterior Spinal Distraction Implant is not currently approved for sale or distribution in the United States.

ABOUT REPLICATION MEDICAL

Replication Medical, Inc. is a developer of proprietary, hydrogel based products for the spinal market and other surgical applications.   Headquartered in Cranbury, New Jersey, the Company is a leader in the design and development of novel biometic hydrogel implants.  

SOURCE Replication Medical, Inc.

Back to top
'/>"/>
SOURCE Replication Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
2. Mayo Clinic Clarifies Diagnosis and Treatment for Rare, Serious Blood Vessel Disease of Brain and Spinal Cord
3. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
4. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
5. Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy
6. CoreSpine Technologies Expands Spinal Disc Site Preparation Efforts
7. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
8. Synapse Biomedical Receives FDA Approval of NeuRx Diaphragm Pacing System (DPS)(TM) For Spinal Cord Injury Breathing Applications
9. New Minimally Invasive Surgical Procedure Restores Quality of Life in Patients With Potentially Debilitating Spinal Condition
10. Markers in Blood and Spinal Fluid, and a New Imaging Agent, Show Promise for Early Detection of Alzheimers
11. Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... RK Logistics Group, Inc. was awarded California ... Fremont, CA headquarters facility where it provides full-spectrum ... San Jose for hi-tech, pharmaceutical and biomedical devices ... its Fremont Innovation District, is excited to strategically partner with ... the hundreds of biotech, pharma and biomed companies throughout the ...
(Date:7/11/2017)... , July 11, 2017 Zymo Research Corp., also known ... that can quantify biological aging in a precise manner using the myDNAge ... Steve Horvath , a professor of human genetics and biostatistics at the ... School of Public Health , Zymo Research,s proprietary DNAge ™ technology ... ...
(Date:7/11/2017)... -- Dr. Echenberg, founder of Echenberg Institute, is announcing a new safe and ... painful intercourse and other painful pelvic pain conditions such as pelvic floor ... ... ... -based start-up company, VuVatech LLC, fills a void in the women,s ...
Breaking Medicine Technology:
(Date:7/20/2017)... ROUGE, La. (PRWEB) , ... July 20, 2017 , ... ... to the staff. Dr. Dunbar received his BS in Biology from LSU, graduating summa ... the Medical School Class President. After his residency in St. Louis, Dr. Dunbar moved ...
(Date:7/20/2017)... ... , ... A budget proposal to switch to an alternate consumer price index, ... is a bad deal for older and disabled Americans, says The Senior Citizens ... more slowly than the conventional one that is currently used to determine the annual ...
(Date:7/20/2017)... ... July 19, 2017 , ... Med Tech Solutions (MTS), ... based Health IT business unit of Constellation Inc., a move that will help the ... of operations in St. Louis, the acquisition is expected to help MTS ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... “Fidget”: a ... Sisk, a retired public high school music and drama teacher who was a summa ... educational career, including a “Teacher of the Year” award. After her retirement from public ...
(Date:7/18/2017)... , ... July 18, 2017 , ... The results of an international clinical trial, led ... therapy for a severe type of muscular dystrophy holds promise for a subgroup of patients. ... Craig McDonald and colleagues at 53 study sites in 18 countries describe the clinical ...
Breaking Medicine News(10 mins):